

Shomik Sengupta Fracs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8787765/publications.pdf>

Version: 2024-02-01

147
papers

5,423
citations

117453

34
h-index

88477

70
g-index

157
all docs

157
docs citations

157
times ranked

7384
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychological Health of Surgeons in a Time of COVID-19. <i>Annals of Surgery</i> , 2023, 277, 50-56.	2.1	59
2	Incorporating intra-lesional injection of mitomycin C in the management algorithm for bladder neck contractures and vesicourethral anastomotic strictures. <i>Journal of Clinical Urology</i> , 2022, 15, 46-53.	0.1	1
3	â€Painâ€free TRUS Bâ€™: a phase 3 doubleâ€blind placeboâ€controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonographyâ€guided prostate biopsy (ANZUP 1501). <i>BJU International</i> , 2022, 129, 591-600.	1.3	5
4	Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. <i>Quality of Life Research</i> , 2021, 30, 345-366.	1.5	8
5	Compliance with followâ€up for patients with stage 1 testicular germ cell tumour. <i>ANZ Journal of Surgery</i> , 2021, 91, 184-186.	0.3	0
6	Impact of radical prostatectomy on bladder function as demonstrated on urodynamics studyâ€A systematic review. <i>Neurourology and Urodynamics</i> , 2021, 40, 582-603.	0.8	7
7	Exploratory models comparing ethiodized oil-glue and gold fiducials for bladder radiotherapy image-guidance. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 77-83.	1.2	0
8	Continuous bladder irrigation after transurethral resection of nonâ€muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review. <i>ANZ Journal of Surgery</i> , 2021, 91, 2592-2598.	0.3	3
9	Testicular seminoma metastases presenting as gastrointestinal malignancy: A case report and review of the literature. <i>ANZ Journal of Surgery</i> , 2021, , .	0.3	0
10	Impact of radiotherapy for localized prostate cancer on bladder function as demonstrated on urodynamics study: A systematic review. <i>Canadian Urological Association Journal</i> , 2021, 15, E664-E671.	0.3	5
11	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021, 12, 5049.	5.8	33
12	Proximal seminal vesicle displacement and margins for prostate cancer radiotherapy. <i>Journal of Medical Radiation Sciences</i> , 2021, 68, 289-297.	0.8	0
13	Impacts of the COVIDâ€™9 pandemic on early detection of prostate cancer in Australia. <i>BJU International</i> , 2021, 128, 6-8.	1.3	5
14	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€™An International Collaborative Multistakeholder Effortâ€. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
15	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020, 78, 893-906.	0.9	112
16	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 469-481.	1.9	29
17	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostateâ€™A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS385-TPS385.	0.8	2
18	Adding mitomycin to Bacillus Calmette-GuÃ©rin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS602-TPS602.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Transperineal prostate biopsy: a review of technique. <i>Translational Andrology and Urology</i> , 2020, 9, 3009-3017.	0.6	29
20	A narrative review of pelvic lymph node dissection in prostate cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 3049-3055.	0.6	9
21	Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 185-195.	0.2	0
22	Surgery for urological cancers. <i>Translational Andrology and Urology</i> , 2020, 9, 3007-3008.	0.6	0
23	Retroperitoneal lymph node dissection for germ cell tumour. <i>Translational Andrology and Urology</i> , 2020, 9, 3103-3111.	0.6	8
24	PD12-08â€fDEVELOPMENT OF A PATIENT-REPORTED SYMPTOM INDEX FOR USE WITH NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS USING MIXED METHODS. <i>Journal of Urology</i> , 2020, 203, e262.	0.2	0
25	MP72-17â€fOSMOTIC CYTOLYTIC EFFECTS OF WATER ON CELL COUNTS â€“ IMPLICATIONS FOR CLINICAL USE OF WATER IRRIGATION TO REDUCE NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
26	Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 667-690.	1.2	52
27	The use of tissue fiducial markers in improving the accuracy of post-prostatectomy radiotherapy. <i>Radiation Oncology Journal</i> , 2019, 37, 43-50.	0.7	8
28	â€œMirrorâ€•ureteric colic caused by proximal ureteric calculus in massively hydronephrotic kidney. <i>Urology Case Reports</i> , 2019, 25, 100892.	0.1	0
29	Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. <i>BJU International</i> , 2019, 123, 36-42.	1.3	12
30	High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 415-421.	0.9	9
31	Hierarchical task analysis for identification of interrelationships between ergonomic, external disruption, and internal disruption in complex laparoscopic procedures. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 3673-3687.	1.3	8
32	EAUâ€“ESMO consensus statements on the management of advanced and variant bladder cancerâ€”an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	0.6	96
33	Delays in prostate cancer care within a hospital network in Victoria, Australia. <i>ANZ Journal of Surgery</i> , 2019, 89, 1599-1604.	0.3	5
34	Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube. <i>European Urology</i> , 2019, 75, 564-567.	0.9	215
35	Fiducial markers: can the urologist do better?. <i>World Journal of Urology</i> , 2019, 37, 1281-1287.	1.2	2
36	The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial. <i>World Journal of Urology</i> , 2019, 37, 1111-1116.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Quality of handwritten surgical operative notes from surgical trainees: a noteworthy issue. ANZ Journal of Surgery, 2019, 89, 176-179.	0.3	8
38	Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and non-malignant prostate epithelial cells. BJU International, 2019, 123, 27-35.	1.3	1
39	Role of pelvic lymph node dissection in bladder cancer: is it better to do more?. Translational Cancer Research, 2019, 8, S180-S182.	0.4	0
40	Prospective randomised controlled trial of written supplement to verbal communication of results to patients at the time of flexible cystoscopy. World Journal of Urology, 2018, 36, 883-887.	1.2	5
41	Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. Annals of Oncology, 2018, 29, 370-376.	0.6	12
42	Interpolation to define clinical tumor stage in prostate cancer using clinical description of digital rectal examination. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e412-e419.	0.7	1
43	Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy. BJU International, 2018, 122, 427-433.	1.3	26
44	Trends in the surgical treatment of benign prostatic hyperplasia in a tertiary hospital. ANZ Journal of Surgery, 2018, 88, 95-99.	0.3	7
45	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells. BJU International, 2018, 121, 971-978.	1.3	39
46	Survival outcomes in elderly men undergoing radical prostatectomy in Australia. ANZ Journal of Surgery, 2018, 88, E189-E193.	0.3	1
47	Survival outcomes of younger men (≥ 55 years) undergoing radical prostatectomy. Prostate International, 2018, 6, 31-35.	1.2	16
48	The impact of the global bacille Calmette-Guérin shortage on treatment patterns: population-based data. BJU International, 2018, 121, 169-172.	1.3	17
49	Putting guidelines into practice: has the era of perioperative chemotherapy arrived?. Translational Andrology and Urology, 2018, 7, S255-S257.	0.6	1
50	Differences between PARTICIPANTS AND NON PARTICIPANTS in a randomised controlled trial - LESSONS LEARNT FROM the ENGAGE study of referral for an exercise program in survivors of prostate cancer. BJU International, 2018, 122, 922-923.	1.3	0
51	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial. Kidney Cancer, 2018, 2, 123-131.	0.2	4
52	Correspondence from specialist surgical outpatient clinics to general practitioners. ANZ Journal of Surgery, 2018, 88, 818-819.	0.3	0
53	A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes. Journal of Contemporary Brachytherapy, 2018, 10, 155-161.	0.4	12
54	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	0.9	80

#	ARTICLE	IF	CITATIONS
55	Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 686-692.	1.9	67
56	Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS531-TPS531.	0.8	4
57	<sc>BCG</sc>+Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned. <i>BJU International</i> , 2017, 119, 55-57.	1.3	1
58	Ergonomics perspective for identifying and reducing internal operative flow disruption for laparoscopic urological surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 5043-5056.	1.3	10
59	Predictors of delay to cystoscopy and adequacy of investigations in patients with haematuria. <i>BJU International</i> , 2017, 119, 19-25.	1.3	15
60	Factors affecting the timeliness and adequacy of haematuria assessment in bladder cancer: a systematic review. <i>BJU International</i> , 2017, 119, 10-18.	1.3	23
61	Bladder cancer diagnosis during haematuria investigation – implications for practice guidelines. <i>BJU International</i> , 2017, 119, 53-54.	1.3	2
62	A Pilot Study: The Role of Radio-Opaque Hydrogel Tissue Marker in the Treatment of Postprostatectomy Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E238-E239.	0.4	0
63	Prostate cancer post-prostatectomy radiotherapy: CT vs MRI for vesico-urethral anastomosis target delineation. <i>Radiotherapy and Oncology</i> , 2017, 125, 113-117.	0.3	7
64	Implementation rates of uro-oncology multidisciplinary meeting decisions. <i>BJU International</i> , 2017, 120, 15-20.	1.3	22
65	Analysis of LDR Outcomes in Clinically Localized Prostate Cancer Incorporating a Significant TURP Cohort: A Community Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E265-E266.	0.4	0
66	Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma. <i>Investigative and Clinical Urology</i> , 2017, 58, 416.	1.0	11
67	Diabetes and elevated urea level predict for uretero-ileal stricture after radical cystectomy and ileal conduit formation. <i>Canadian Urological Association Journal</i> , 2017, 11, 88.	0.3	4
68	A Systematic Review of Ileal Conduit and Neobladder Outcomes in Primary Bladder Cancer. <i>Urology</i> , 2016, 96, 74-79.	0.5	27
69	Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the <sc>PROSTATE C</sc>ancer <sc>REGISTRY</sc>. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 247-254.	0.9	14
70	Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery – a single center experience. <i>BJU International</i> , 2016, 117, 50-53.	1.3	25
71	Trends in incidence and survival for upper tract urothelial cancer (<sc>UTUC</sc>) in the state of Victoria – Australia. <i>BJU International</i> , 2016, 117, 45-49.	1.3	16
72	Pembrolizumab with ChemoRadiotherapy for Muscle Invasive Bladder Cancer: the ANZUP PCR-MIB trial. <i>Annals of Oncology</i> , 2016, 27, vi294.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Changing practice of pelvic lymph node dissection in management of primary bladder cancer. <i>Minerva Urologica e Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2016, 68, 106-11.	3.9	4
74	The role of cystectomy in elderly patients – a multicentre analysis. <i>BJU International</i> , 2015, 116, 73-79.	1.3	41
75	BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). <i>BMC Cancer</i> , 2015, 15, 432.	1.1	15
76	Lymphadenectomy with radical cystectomy at an Australian tertiary referral institution: time trends and impact on oncological outcomes. <i>ANZ Journal of Surgery</i> , 2015, 85, 535-539.	0.3	4
77	Prostate cancer screening in Primary Health Care: the current state of affairs. <i>SpringerPlus</i> , 2015, 4, 78.	1.2	9
78	The Australian and New Zealand Urological and Prostate (ANZUP) Cancer Trials Group – a new cooperative cancer trials group in genitourinary oncology. <i>BJU International</i> , 2015, 115, 856-858.	1.3	0
79	Human error identification for laparoscopic surgery: Development of a motion economy perspective. <i>Applied Ergonomics</i> , 2015, 50, 113-125.	1.7	8
80	Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile?. <i>Journal of Clinical Oncology</i> , 2015, 33, 415-415.	0.8	2
81	The effects of nonspecific HIF1 α inhibitors on development of castrate resistance and metastases in prostate cancer. <i>Cancer Medicine</i> , 2014, 3, 245-251.	1.3	36
82	Population-based analysis of prostate-specific antigen (PSA) screening in younger men (≤ 55 years) in Australia. <i>BJU International</i> , 2014, 113, 77-83.	1.3	15
83	Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre – impact on clinical decision-making and implications for patient inclusion. <i>BJU International</i> , 2014, 114, 50-54.	1.3	70
84	Urological Society of Australia and New Zealand's alignment with the <i>BJU International</i> : a collaborative success magnified by a supplement journal. <i>BJU International</i> , 2014, 114, 3-5.	1.3	82
85	Editorial Comment from Dr Sengupta and Dr Webb to <i>Journal of Urology</i> : Adherence and accuracy of the recent guidelines. <i>International Journal of Urology</i> , 2013, 20, 412-412.	0.5	0
86	429 IMPACTS OF A URO-ONCOLOGY MULTIDISCIPLINARY MEETING ON CLINICAL DECISION MAKING. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
87	Gene Expression Profiling of Localized Prostate Cancer: Getting Answers to the Questions That Really Matter. <i>Journal of Clinical Oncology</i> , 2013, 31, 3295-3296.	0.8	2
88	USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer. <i>BJU International</i> , 2013, 112, 74-82.	1.3	20
89	Effects of angiotensin-converting enzyme (ACE) inhibitors on the outcomes of patients receiving primary radiotherapy for prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e16016-e16016.	0.8	0
90	Use of a barbed suture for continuous urethro-vesical anastomosis during robot-assisted laparoscopic radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2012, 6, 241-242.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Predictors of positive surgical margins at open and robot-assisted laparoscopic radical prostatectomy: a single surgeon series. <i>Journal of Robotic Surgery</i> , 2012, 6, 311-316.	1.0	3
92	Trends in the use of of nephron-sparing surgery (NSS) at an Australian tertiary referral centre: an analysis of surgical decision-making using the R.E.N.A.L. nephrometry scoring system. <i>BJU International</i> , 2012, 109, 1341-1344.	1.3	18
93	Renal lesions with low R.E.N.A.L nephrometry score are associated with more indolent renal cell carcinomas (RCCs) or benign histology: findings in an Australian cohort. <i>BJU International</i> , 2012, 109, 44-47.	1.3	38
94	Algorithm for selecting men for pelvic lymph node dissection (PLND) during radical prostatectomy based on clinical risk factors in an Australian population. <i>BJU International</i> , 2012, 109, 48-51.	1.3	7
95	A New Preoperative Nomogram to Predict Minimal Prostate Cancer: Accuracy and Error Rates Compared to Other Tools to Select Patients for Active Surveillance. <i>Journal of Urology</i> , 2011, 186, 1811-1817.	0.2	20
96	Single-layer anatomical reconstruction of the vesico-urethral anastomosis during robot-assisted laparoscopic prostatectomy (RALP). <i>BJU International</i> , 2011, 107, 340-343.	1.3	8
97	The effect of hypertension and diabetes on the degree of renal function deterioration after unilateral nephrectomy. <i>BJU International</i> , 2011, 108, 1508-1512.	1.3	12
98	Use of ultrasound and surgery in adults with acute scrotal pain. <i>ANZ Journal of Surgery</i> , 2011, 81, 366-370.	0.3	8
99	Early release of pedicles and posterior development of the "Veil of Aphrodite"™ in robotic-assisted laparoscopic prostatectomy (RALP). <i>BJU International</i> , 2010, 106, 1856-1861.	1.3	3
100	After radical retropubic prostatectomy "insignificant"™ prostate cancer has a risk of progression similar to low-risk "significant"™ cancer. <i>BJU International</i> , 2008, 101, 170-174.	1.3	33
101	Association of Abnormal Preoperative Laboratory Values with Survival After Radical Nephrectomy for Clinically Confined Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2008, 71, 278-282.	0.5	37
102	Prostate Specific Antigen Kinetics in the Management of Prostate Cancer. <i>Journal of Urology</i> , 2008, 179, 821-826.	0.2	16
103	Tumor-Infiltrating Foxp3 ⁺ CD4 ⁺ CD25 ⁺ T Cells Predict Poor Survival in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 2075-2081.	3.2	188
104	Prediction of Radial Distance of Extraprostatic Extension From Pretherapy Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 411-418.	0.4	18
105	Early effects of pharmacological androgen deprivation in human prostate cancer. <i>BJU International</i> , 2007, 99, 60-67.	1.3	27
106	Renal cell carcinoma: vena caval involvement. <i>BJU International</i> , 2007, 99, 1239-1244.	1.3	94
107	1403: "Insignificant" Prostate Cancer Treated by Radical Retropubic Prostatectomy has a Risk of Progression Similar to Low-Risk "Significant" Cancer. <i>Journal of Urology</i> , 2007, 177, 462-462.	0.2	1
108	Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival. <i>Journal of Urology</i> , 2006, 175, 1684-1690.	0.2	22

#	ARTICLE	IF	CITATIONS
109	Detectable Prostate Specific Antigen Between 60 and 120 Days Following Radical Prostatectomy for Prostate Cancer: Natural History and Prognostic Significance. <i>Journal of Urology</i> , 2006, 176, 559-563.	0.2	29
110	Malignant Hypertension during Cryoablation of an Adrenal Gland Tumor. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 573-575.	0.2	57
111	Impact of Familial and Hereditary Prostate Cancer on Cancer Specific Survival After Radical Retropubic Prostatectomy. <i>Journal of Urology</i> , 2006, 176, 1118-1121.	0.2	18
112	Impact of Patient Age at Treatment on Outcome Following Radical Retropubic Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2006, 175, 952-957.	0.2	59
113	Rare Expression of KIT and Absence of KIT Mutations in High Grade Renal Cell Carcinoma. <i>Journal of Urology</i> , 2006, 175, 53-56.	0.2	21
114	Simple graphic method for estimation of prostate-specific antigen doubling time. <i>Urology</i> , 2006, 67, 408-409.	0.5	7
115	The management of superficial transitional cell carcinoma of the bladder. <i>Urology</i> , 2006, 67, 48-54.	0.5	45
116	Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy. <i>Urology</i> , 2006, 68, 94-98.	0.5	5
117	Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. <i>Urology</i> , 2006, 68, 810-814.	0.5	10
118	Does butyrate protect from colorectal cancer?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 209-218.	1.4	171
119	The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. <i>Cancer</i> , 2006, 106, 304-312.	2.0	60
120	Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. <i>Cancer</i> , 2006, 106, 2630-2635.	2.0	27
121	Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. <i>Cancer</i> , 2006, 107, 46-53.	2.0	69
122	Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. <i>Cancer</i> , 2006, 107, 521-529.	2.0	111
123	Is nephron-sparing surgery for small renal masses underused?. <i>Nature Reviews Urology</i> , 2006, 3, 412-413.	1.4	0
124	Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. <i>Cancer Research</i> , 2006, 66, 3381-3385.	0.4	788
125	Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series. <i>BJU International</i> , 2005, 96, 54-57.	1.3	21
126	The development of prostate cancer despite late onset androgen deficiency. <i>International Journal of Urology</i> , 2005, 12, 847-848.	0.5	7

#	ARTICLE	IF	CITATIONS
127	Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. <i>Cancer</i> , 2005, 104, 511-520.	2.0	231
128	Surgery for metastatic renal cell cancer. <i>World Journal of Urology</i> , 2005, 23, 155-160.	1.2	11
129	The Influence of Specific Luminal Factors on the Colonic Epithelium: High-Dose Butyrate and Physical Changes Suppress Early Carcinogenic Events in Rats. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 549-559.	0.7	28
130	Is radical prostatectomy of benefit in men with localized prostate cancer?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 608-609.	4.3	1
131	RE: THE ACCURACY OF 250 FINE NEEDLE BIOPSIES OF RENAL TUMORS. <i>Journal of Urology</i> , 2005, 174, 2422-2422.	0.2	5
132	PREOPERATIVE PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AND VELOCITY ARE STRONG AND INDEPENDENT PREDICTORS OF OUTCOMES FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 174, 2191-2196.	0.2	97
133	Isolated vasculitis of the bladder. <i>Urology</i> , 2005, 65, 797.	0.5	11
134	Lessons learned in the surgical management of renal cell carcinoma. <i>Urology</i> , 2005, 66, 36-42.	0.5	14
135	B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma. <i>Urology</i> , 2005, 66, 10-14.	0.5	48
136	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17174-17179.	3.3	723
137	Development of a Chronic Colonic Intubation Model in Rats for the Study of Luminal Factors in Colonic Diseases. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 256-263.	0.7	3
138	Left paraduodenal hernia: Case report and review of the literature. <i>ANZ Journal of Surgery</i> , 2002, 72, 69-71.	0.3	37
139	Colonic epithelial atrophy induced by a fibre-free diet in rats is reversed by minimal amounts of luminal butyrate, but only in the short term. <i>ANZ Journal of Surgery</i> , 2002, 72, 871-876.	0.3	7
140	Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 1759-1765.	0.7	84
141	Local excision of rectal cancer. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 1345-1361.	0.7	233
142	Dietary fiber and colorectal neoplasia. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 1016-1033.	0.7	35
143	Use of a computer-controlled bipolar diathermy system in radical prostatectomies and other open urological surgery. <i>ANZ Journal of Surgery</i> , 2001, 71, 538-540.	0.3	62
144	Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 923-926.	1.4	44

#	ARTICLE	IF	CITATIONS
145	MCP-3 in inflammatory bowel disease Reply. Gut, 2000, 47, 155-155.	6.1	2
146	Transitional cell carcinoma growing along an indwelling nephrostomy tube track. BJU International, 1998, 82, 591-591.	1.3	22
147	A right anomalous renal artery originating from the superior mesenteric artery. ANZ Journal of Surgery, 0, , .	0.3	0